Advanced Enzyme Tech Stock Screener | Share Price & Fundamental Analysis
ADVENZYMES
Biotechnology
Share Price NSE
₹281.40
▲
2.60 (0.93%)
Share Price BSE
₹281.15
▲
2.30 (0.82%)
Track Advanced Enzyme Tech share price live with TickJournal's free stock screener.
Analyze Advanced Enzyme Tech share price history trends and compare 52-week high low
levels.
Record your trades in TickJournal's free trading journal and track your portfolio performance.
Advanced Enzyme Tech Market Cap
₹3,050.01 Cr.
ADVENZYMES P/E Ratio (TTM)
19.28
Advanced Enzyme Tech P/B Ratio
2.01
EPS (TTM)
₹11.72
Dividend Yield
1.95%
Debt to Equity
0.03
ADVENZYMES 52 Week High
₹360.35
Advanced Enzyme Tech 52 Week Low
₹255.30
Operating Margin
29.00%
Profit Margin
22.40%
ADVENZYMES Revenue (TTM)
₹192.00
EBITDA
₹69.00
Net Income
₹43.00
Total Assets
₹1,621.00
Total Equity
₹1,469.00
Advanced Enzyme Tech Share Price History - Stock Screener Chart
Screen ADVENZYMES historical share price movements with interactive charts. Analyze price trends and patterns.
Advanced Enzyme Tech Company Profile - Fundamental Screener
Screen Advanced Enzyme Tech company fundamentals and business profile. Use our stock screener to analyze sector, industry, and key company metrics
for ADVENZYMES shares.
Sector
Healthcare
Industry
Biotechnology
Sub-Sector
Biotechnology
Segment
E
ISIN
INE837H01020
Advanced Enzyme Tech Balance Sheet Screener
Screen ADVENZYMES balance sheet fundamentals including assets, liabilities, and equity. Use our screener tool to analyze financial health and share price valuation
metrics.
| Item | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||
| Total Assets | 1,621 | 1,536 | 1,422 | 1,268 | 1,153 | 979 | 811 | 732 | 589 | 451 |
| Current Assets | 880 | 810 | 722 | 604 | 516 | 376 | 282 | 211 | 138 | 140 |
| Fixed Assets | 679 | 650 | 649 | 619 | 601 | 563 | 496 | 491 | 421 | 286 |
| Liabilities | ||||||||||
| Total Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Current Liabilities | 56 | 58 | 60 | 67 | 54 | 52 | 41 | 51 | 42 | 56 |
| Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Shareholders' Equity | ||||||||||
| Total Equity | 1,469 | 1,371 | 1,284 | 1,140 | 1,031 | 867 | 705 | 582 | 485 | 283 |
| Share Capital | 22 | 22 | 22 | 22 | 22 | 22 | 22 | 22 | 22 | 22 |
| Reserves & Surplus | 1,399 | 1,302 | 1,213 | 1,066 | 948 | 817 | 657 | 537 | 442 | 256 |
Advanced Enzyme Tech Income Statement Screener - Profit & Revenue Analysis
Screen Advanced Enzyme Tech income statement and profit fundamentals.
Analyze ADVENZYMES quarterly results,
revenue growth, EBITDA, net profit margins, and EPS using TickJournal's fundamental screener for Advanced Enzyme Tech share price evaluation.
| Item | 2025-Dec | 2025-Sept | 2025-Jun | 2025-Mar | 2024-Dec | 2024-Sept | 2024-Jun | 2024-Mar | 2023-Dec | 2023-Sept | 2023-Jun | 2023-Mar | 2022-Dec | 2022-Sept | 2022-Jun |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 192 | 195 | 195 | 176 | 177 | 156 | 162 | 167 | 175 | 164 | 154 | 150 | 151 | 143 | 123 |
| Expenses | 123 | 125 | 130 | 122 | 114 | 104 | 103 | 118 | 107 | 107 | 103 | 99 | 100 | 99 | 90 |
| EBITDA | 69 | 70 | 65 | 54 | 63 | 52 | 58 | 50 | 68 | 57 | 51 | 51 | 50 | 44 | 33 |
| Operating Profit % | 29.00% | 33.00% | 30.00% | 27.00% | 33.00% | 29.00% | 33.00% | 26.00% | 33.00% | 33.00% | 30.00% | 29.00% | 29.00% | 29.00% | 26.00% |
| Depreciation | 10 | 10 | 10 | 10 | 9 | 9 | 9 | 9 | 9 | 9 | 9 | 8 | 9 | 9 | 9 |
| Interest | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Profit Before Tax | 58 | 60 | 55 | 44 | 53 | 42 | 49 | 40 | 59 | 48 | 41 | 42 | 41 | 34 | 24 |
| Tax | 15 | 15 | 15 | 17 | 14 | 9 | 14 | 10 | 16 | 13 | 12 | 10 | 13 | 8 | 6 |
| Net Profit | 43 | 45 | 40 | 27 | 39 | 33 | 35 | 30 | 43 | 35 | 29 | 32 | 28 | 26 | 18 |
| EPS | 3.80 | 3.87 | 3.57 | 2.37 | 3.36 | 2.94 | 3.05 | 2.53 | 3.74 | 3.08 | 2.58 | 2.87 | 2.63 | 2.34 | 1.60 |
Advanced Enzyme Tech Cash Flow Screener - Liquidity Fundamentals
Screen ADVENZYMES cash flow statements and liquidity fundamentals. Analyze operating, investing, and financing activities using our stock screener for share price
strength assessment.
| Item | 2025-March | 2024-March | 2023-March | 2022-March | 2021-March | 2020-March | 2019-March | 2018-March | 2017-March | 2016-March |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Activities | 143 | 141 | 140 | 122 | 163 | 141 | 129 | 116 | 107 | 93 |
| Investing Activities | -90 | -65 | -286 | 2 | -27 | -43 | -124 | -60 | -60 | -10 |
| Financing Activities | -73 | -59 | -26 | -49 | -26 | -39 | -43 | -2 | -65 | -63 |
| Net Cash Flow | -20 | 17 | -171 | 75 | 109 | 60 | -38 | 54 | -18 | 21 |
Advanced Enzyme Tech Shareholding Pattern Screener
See Advanced Enzyme Tech shareholding pattern with promoter, FII, and DII holdings.
Check Advanced Enzyme Tech promoter holding and ownership changes for ADVENZYMES on TickJournal.
| Item | 2025-Mar | 2025-Jun | 2025-Sept | 2025-Dec | 2024-Mar | 2024-Jun | 2024-Sept | 2024-Dec |
|---|---|---|---|---|---|---|---|---|
| Promoter Holding | 43.08% | 43.08% | 43.07% | 43.04% | 43.49% | 43.02% | 42.95% | 42.93% |
| FII Holding | 11.90% | 23.46% | 25.41% | 25.86% | 23.01% | 12.03% | 12.63% | 12.58% |
| DII Holding | 8.19% | 8.45% | 6.41% | 5.51% | 7.56% | 8.08% | 8.02% | 8.18% |
| Govt Holding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Public Holding | 16.68% | 16.92% | 16.95% | 17.44% | 15.43% | 16.42% | 16.04% | 16.11% |
| Other Holding | 20.16% | 8.10% | 8.15% | 8.15% | 10.51% | 20.45% | 20.36% | 20.21% |
| Shareholder Count | 65,322 | 67,589 | 69,637 | 68,051 | 68,640 | 65,222 | 66,758 | 67,351 |
Advanced Enzyme Tech Share Dividend Screener - Share Yield Analysis
Check Advanced Enzyme Tech dividend history with payout and yield data.
View Advanced Enzyme Tech dividend details including ex-dates and amounts for ADVENZYMES stock.
| Period | Dividend Per Share | Dividend Yield |
|---|---|---|
| 2026-March | ₹0.00 | 0.00% |
| 2025-March | ₹5.20 | 2.04% |
| 2024-March | ₹5.10 | 1.83% |
| 2023-March | ₹1.00 | 0.29% |
| 2022-March | ₹1.00 | 0.42% |
| 2021-March | ₹0.90 | 0.32% |
| 2020-March | ₹0.60 | 0.17% |
| 2019-March | ₹0.60 | 0.42% |
| 2018-March | ₹0.50 | 0.27% |
| 2017-March | ₹0.40 | 0.19% |
Advanced Enzyme Tech Stock Index Membership
See which indices include Advanced Enzyme Tech stock.
Check ADVENZYMES index membership in NIFTY 50, SENSEX, and other indices on TickJournal.
BSE 1000
BSE INDEX BSE HC
BSE INDEX SMLCAP
NIFTY MICROCAP250
NIFTY TOTAL MKT
Advanced Enzyme Tech Market Events Screener - Corporate Actions
Get Advanced Enzyme Tech corporate actions including splits, bonuses, and buybacks.
Check Advanced Enzyme Tech stock events that may affect ADVENZYMES share price.
| Announcement Date | Record Date | Event Type | Information | Price Impact |
|---|---|---|---|---|
| 2026-01-31 | 2026-01-31 | Quarterly Result Announcement | NA | 9.01% |
| 2025-11-12 | 2025-11-12 | Quarterly Result Announcement | NA | -3.00% |
| 2025-08-02 | 2025-08-02 | Quarterly Result Announcement | NA | 9.08% |
| 2025-07-30 | 2025-07-30 | Annual General Meeting | NA | 17.52% |
| 2025-07-23 | 2025-07-23 | Dividend | ₹ 1.20 /share | 14.50% |
| 2025-05-16 | 2025-05-17 | Dividend | ₹ 4.00 /share | -2.14% |
| 2025-05-13 | 2025-05-13 | Quarterly Result Announcement | NA | 3.69% |
| 2025-02-08 | 2025-02-08 | Quarterly Result Announcement | NA | 0.59% |
| 2024-11-09 | 2024-11-09 | Quarterly Result Announcement | NA | 8.49% |
| 2024-07-25 | 2024-07-25 | Annual General Meeting | NA | -0.77% |
| 2024-07-18 | 2024-07-18 | Dividend | ₹ 1.10 /share | -4.60% |
| 2024-05-17 | 2024-05-18 | Dividend | ₹ 4.00 /share | -5.22% |
| 2023-08-04 | 2023-08-05 | Dividend | ₹ 1.00 /share | 18.08% |
| 2023-05-19 | 2023-05-20 | Dividend | ₹ 4.00 /share | -4.88% |
| 2022-08-11 | 2022-08-12 | Dividend | ₹ 1.00 /share | -7.09% |
Advanced Enzyme Tech Competitors Screener - Peer Comparison
Screen ADVENZYMES competitors and compare share prices across peer stocks. Use our screener to analyze sector peers, fundamentals, and relative performance for better
stock selection.
| Company | Market Cap | P/E Ratio | Revenue | YoY Growth | Net Profit | RSI |
|---|---|---|---|---|---|---|
| Anthem Biosciences | 37,115 | 77.29 | 1,930 | 30.15% | 451 | 51.31 |
| Advanced Enzyme Tech | 3,050 | 19.28 | 670 | 1.44% | 134 | 45.10 |
| Genesis IBRC | 439 | -1979.60 | 4 | % | 0 | 58.47 |
| Vivo Bio Tech | 53 | 11.30 | 52 | 13.19% | 7 | 44.70 |
| Shree Ganesh Bio-Tech | 24 | -58.00 | 24 | 14.55% | 0 | 53.60 |
| Genomic Valley Biotech | 7 | -178.33 | 1 | 300.00% | 0 | 38.37 |
Advanced Enzyme Tech Company Announcements - News Screener
Screen ADVENZYMES latest company announcements and news updates. Filter stock news, results, and material events using our screener for share price impact analysis.
| Date | Update | Actions |
|---|---|---|
| 2026-03-31 | Closure of Trading Window | - |
| 2026-03-11 | Announcement under Regulation 30 (LODR)-Change in Management | - |
| 2026-02-13 | Announcement under Regulation 30 (LODR)-Credit Rating | - |
| 2026-02-10 | Announcement under Regulation 30 (LODR)-Newspaper Publication | - |
| 2026-02-07 | Announcement under Regulation 30 (LODR)-Earnings Call Transcript | - |
| 2026-02-04 | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome | - |
| 2026-02-02 | Announcement under Regulation 30 (LODR)-Newspaper Publication | - |
| 2026-01-31 | Announcement under Regulation 30 (LODR)-Investor Presentation | - |
| 2026-01-31 | Announcement under Regulation 30 (LODR)-Press Release / Media Release | - |
| 2026-01-31 | Update On The Judicial Proceedings Against Advanced Supplementary Technologies Corporation USA (Step Down Wholly Owned Subsidiary) [AST] | - |
| 2026-01-31 | Announcement under Regulation 30 (LODR)-Acquisition | - |
| 2026-01-31 | Unaudited Financial Results (Standalone & Consolidated) Of The Company For The Quarter And Nine Months Ended December 31 2025 | - |
| 2026-01-31 | Board Meeting Outcome for Outcome Of Board Meeting Held On January 31 2026 | - |
| 2026-01-28 | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation | - |
| 2026-01-23 | Board Meeting Intimation for Approval Of Un-Audited Financial Results (Standalone And Consolidated) Of The Company For The Quarter And Nine Months Ended December 31 2025. | - |
| 2026-01-15 | Update - Intimation Regarding Conversion Of Statutory Auditors Firm From M S K A & Associates To M S K A & Associates LLP | - |
| 2026-01-09 | Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018 | - |
| 2025-12-26 | Closure of Trading Window | - |
| 2025-11-17 | Announcement under Regulation 30 (LODR)-Earnings Call Transcript | - |
| 2025-11-13 | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome | - |